When 80,000 blood samples meet virtual reality: My journey from a proteomics paper to a VR molecular laboratory
When 80,000 blood samples meet virtual reality: My journey from a proteomics paper to a VR molecular lab The email from GEN landed in my inbox at 6:47 a.m. Alamar Biosciences and Nightingale Health. 80,000 UK Biobank samples. NULISA platform. Hundreds of blood proteins. Early biomarkers for Alzheimer’s and Parkinson’s. I clicked the link while my coffee still steamed, and felt…
A researcher received an email about a study from Alamar Biosciences and Nightingale Health involving 80,000 blood samples from the UK Biobank, which identified early biomarkers for Alzheimer and Parkinson diseases. The researcher, with a background in bioinformatics, used a virtual reality tool called NexoPeek to visualize the 3D structure of a protein called TREM2.
The tool allowed for interactive exploration of the protein structure, including scaling, rotating, and analyzing its domains. NexoPeek also features AI-powered pocket prediction, structural alignment, and integration with various databases such as RCSB PDB, UniProtKB, and AlphaFold DB. Additionally, the tool offers guided tours and interactive lessons on various biotechnological topics, including CRISPR-Cas9 and protein structures.
Written by urgent.news from Dev.to's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
